SRDX Past Earnings image   This SRDX past earnings page last updated 7/29/2022
SRDX Past Earnings
PeriodPast Earnings DateAdj. EPS
Q3 20227/27/2022-0.340
Q2 20224/27/2022-0.220
Q1 20222/3/2022-0.130
Q4 202111/10/2021-0.100
Q3 20218/4/2021-0.170
Q2 20214/28/20210.620
Q1 20212/9/20210.020
Q4 202011/4/2020-0.180
Q3 20208/5/20200.210
Q2 20204/29/20200.040
Q1 20202/5/20200.050
Q4 201910/31/20190.370
Q3 20197/31/20190.150
Q2 20195/1/20190.070
Q1 20191/30/20190.12
Q4 201811/9/20180.05
Q3 20188/6/20180.27
Q2 20185/2/20180.15
Q1 20182/8/20180.1
Q4 201711/8/20170.18
Q3 20178/3/20170.09
Q2 20174/27/20170.05
Q1 20172/2/20170.19
Q4 201611/16/20160.26
Q3 20167/28/20160.37
Q2 20165/2/20160.2
Q1 20161/28/20160.38
Q4 201511/10/20150.3
Q3 20158/5/20150.26
Q2 20154/30/20150.19
Q1 20151/29/20150.25
Q4 201411/6/20140.26
Q3 20147/31/20140.27
Q2 20145/1/20140.22
Q1 20141/30/20140.21
Q4 201311/5/20130.26
Q3 20137/31/20130.21
Q2 20135/7/20130.28
Q1 20131/30/20130.29
Q4 201211/6/20120.19
Q3 20128/1/20120.18
SRDX Past Revenue
PeriodPast Earnings DateGAAP
Q3 20227/27/20220.02B
Q2 20224/27/20220.03B
Q1 20222/3/20220.02B
Q4 202111/10/20210.02B
Q3 20218/4/20210.02B
Q2 20214/28/20210.03B
Q1 20212/9/20210.02B
Q4 202011/4/20200.02B
Q3 20208/5/20200.03B
Q2 20204/29/20200.02B
Q1 20202/5/20200.02B
Q4 201910/31/20190.03B
Q3 20197/31/20190.02B
Q2 20195/1/20190.02B
Q1 20191/30/201922.24M
Q4 201811/9/201823.04M
Q3 20188/6/201822.23M
Q2 20185/2/201819.06M
Q1 20182/8/201817.01M
Q4 201711/8/201720.06M
Q3 20178/3/201717.79M
Q2 20174/27/201717.50M
Q1 20172/2/201717.76M
Q4 201611/16/201618.15M
Q3 20167/28/201619.97M
Q2 20165/2/201616.70M
Q1 20161/28/201616.54M
Q4 201511/10/201517.36M
Q3 20158/5/201515.91M
Q2 20154/30/201514.41M
Q1 20151/29/201514.21M
Q4 201411/6/201415.30M
Q3 20147/31/201414.62M
Q2 20145/1/201413.60M
Q1 20141/30/201413.88M
Q4 201311/5/201314.30M
Q3 20137/31/201314.30M
Q2 20135/7/201313.70M
Q1 20131/30/201313.85M
Q4 201211/6/201213.80M
Q3 20128/1/201214.00M
Quotes delayed 20 minutes

Email EnvelopeFree SRDX Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
10 Most Oversold S&P 500 Stocks
10 Most Overbought S&P 500 Stocks
10 ETFs With Stocks Insiders Are Buying
10 ETFs With Most Upside To Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active S&P Call & Put Options
Surmodics (SRDX) is categorized under the Healthcare sector; to help you further research past earnings across stocks, below are some other companies in the same sector:

SRGA Past Earnings
SRNE Past Earnings
SRPT Past Earnings
SRRA Past Earnings
SRRK Past Earnings
SRTS Past Earnings
SSKN Past Earnings
STAA Past Earnings
STAB Past Earnings
STE Past Earnings

SRDX Past Earnings Q&A

What was the best and worst SRDX past earnings results?
For Surmodics, I'm wondering what the company's very best and worst earnings results have been, on an earnings per share basis?

✔️Accepted answer: The highest SRDX past earnings result in our data set was 0.620/share posted in Q2 2021, while the lowest was in Q3 2022 when SRDX posted -0.340/share.

  Suggested answer: The biggest top line earnings performance — aka revenue — quarter was in Q2 2021 when SRDX reported 0.03B in revenue, while the quarter with the lowest revenue in our data set was Q2 2014 at 13.60M of revenue.

  Suggested answer: There are 41 SRDX past earnings results in our data set.

On this page we presented the SRDX past earnings date information for Surmodics. Reviewing that SRDX Past Earnings for the company, we see that the highest past earnings result in our data set was in Q2 2021, when SRDX posted adjusted EPS of 0.620/share. Meanwhile the lowest SRDX past earnings result was in Q3 2022, when SRDX posted adjusted EPS of -0.340/share. Turning to top line revenue performance, the biggest revenue quarter in our data set was seen in Q2 2021 when SRDX reported 0.03B in revenue, while the smallest revenue quarter was Q2 2014 when SRDX reported 13.60M in revenue.

Any self directed investor doing their due diligence on SRDX or any other given stock can benefit from researching all of the Surmodics past earnings — and here, we present each quarter's result all together on one page for easy comparison. Studying this information can help when projecting future earnings, as well as determining whether the past earnings trajectory justifies the current stock value. That's why we bring you PastEarnings.com to make it easy for investors to investigate Surmodics past earnings, or the past earnings information for any stock in our coverage universe. And in your continued research we hope you will be sure to check out the further links included for earnings surprises history (beat/miss data) as well as next earnings dates for SRDX. Thanks for visiting, and the next time you need to research SRDX past earnings or those of another stock, we hope you'll think of our site, as your go-to past earnings research resource of choice.

Recommended: Institutional Holders of PTY, Funds Holding RWDC, CXDC YTD Return.

 

SRDX Past Earnings | www.PastEarnings.com | Copyright © 2020 - 2022, All Rights Reserved

Nothing in PastEarnings.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.